Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model

May 17th 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

Dr. Alkharabsheh on Remaining Challenges in High-Risk CLL

May 11th 2021

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL

May 6th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Dr. Alkharabsheh on Emerging Treatment Options in CLL

May 5th 2021

Omar Alkharabsheh, MD, discusses emerging treatment options in chronic lymphocytic leukemia.

Umbralisib/Ublituximab Plus Venetoclax Triplet Moves Into Phase 3 Testing as Phase 2 Trial Completes Accrual in CLL

May 4th 2021

Patient enrollment has commenced for the randomized phase 3 ULTRA-V trial, which will evaluate the efficacy of a time-limited combination of umbralisib plus ublituximab and venetoclax vs continuous umbralisib/ublituximab in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia.

Dr. Barrientos on Selecting Between BCL-2 Inhibitors and BTK Inhibitors in CLL

May 3rd 2021

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Zanubrutinib Shows Noninferiority, Improved Safety Vs Ibrutinib in Relapsed/Refractory CLL

April 28th 2021

Zanubrutinib demonstrated noninferiority in objective response rates and a trend toward improved progression-free survival when compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Shadman on the Emergence of Third-Generation BTK Inhibitors in CLL

April 23rd 2021

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Dr. Barrientos on Treatment Considerations for CLL

April 20th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.

Dr. Barrientos on the Shift Away From Chemoimmunotherapy in CLL

April 19th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Rogers on the Safety Profile of Ianalumab/Ibrutinib in CLL

April 14th 2021

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.

Dr. Rogers on the Next Steps With Obinutuzumab/Ibrutinib/Venetoclax in CLL

April 12th 2021

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Barr on the Next Steps With Umbralisib/Ublituximab/Venetoclax in CLL

April 9th 2021

Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.

Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies

April 8th 2021

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Dr. Barr on the Safety Profile of Umbralisib/Ublituximab/Venetoclax in CLL

April 8th 2021

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Dr. Shadman on Considerations for BTK inhibitors in CLL

April 7th 2021

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

April 6th 2021

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Dr. Shadman on Continuous Vs Time-Limited Treatments in CLL

April 2nd 2021

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Duvelisib Granted Positive EU Opinion for Relapsed/Refractory CLL and Refractory Follicular Lymphoma

April 1st 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

Rolling Submission of BLA to FDA Completed for Ublituximab/Umbralisib in CLL

March 29th 2021

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.